ArticleScientific reports2021
Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Combination therapy for myopia control using defocus incorporated multiple segments spectacles in children refractory to higher-dose atropine.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- The Changing Natural History of Anisometropia: A Scoping Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Association Between Pupil Area and the Efficacy of Peripheral Defocus Spectacle Lenses in Myopia Control.Translational vision science & technology · 2026Article
- Artificial intelligence-based quantitative analysis of interocular retinal vascular differences in school-age children with mild to moderate anisometropia.Frontiers in medicine · 2026Article
- Effectiveness of a split-dose, twice-daily low-dose atropine monocular treatment in children with anisometropia: a retrospective study.International ophthalmology · 2025Article
- Evaluating the effect of 0.125% atropine on foveal microvasculature using optical coherence tomography angiography.Scientific reports · 2025Article
- Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study.PloS one · 2025Article
- The Effect of Alternating Monocular Instillation of 0.125% Atropine in Korean Children with Progressive Myopia.Journal of clinical medicine · 2024Article
- Effectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.Frontiers in pharmacology · 2024Article
- Treatment of Myopia with Atropine 0.125% Once Every Night Compared with Atropine 0.125% Every Other Night: A Pilot Study.Journal of clinical medicine · 2023Article
- IMI 2023 Digest.Investigative ophthalmology & visual science · 2023Article
- Efficacy of Myopia Control and Distribution of Corneal Epithelial Thickness in Children Treated with Orthokeratology Assessed Using Optical Coherence Tomography.Journal of personalized medicine · 2022Article
- Retinal vasculature changes after 0.125% atropine treatment in children with myopia measured using optical coherence tomography angiography: A pilot study.Taiwan journal of ophthalmologyArticle
- Anisometropia in children: Current understanding and clinical implications.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
The aim of the study is to determine the effects of monocular 0.125% atropine daily treatment on the longer axial length (AL) eyes in children with pediatric anisometropia. This was a retrospective cohort study. The charts of children with anisometropia (aged 6-15 years) who had a > 0.2-mm difference in AL between the two eyes were reviewed. Children who received monocular treatment of 0.125% atropine in the eye with longer AL were included for final analysis. The main outcome measure was the difference in AL between the two eyes after treatment. Regression analysis was used to model the changes in AL according to the time of treatment in both eyes. Finally, forty eyes in 20 patients (mean age 10.2 years) were included in the analyses. During the treatment period, AL was controlled in the treated eyes (p = 0.389) but elongated significantly in the untreated eyes (p < 0.001). The difference in AL between the treated and untreated eyes decreased from 0.57 to 0.22 mm (p < 0.001) after the 1-year treatment period. In the regression model, the best fit for the relationship between changes in AL and time during the treatment period in the treated eyes was the quadratic regression model with a concave function. In conclusion, these data suggest that 0.125% atropine daily is an effective treatment to reduce the interocular difference of AL in eyes with axial anisometropia. This pilot study provides useful information for future prospective and larger studies of atropine for the treatment of pediatric axial anisometropia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.